mTOR Regulation of Metabolism in Hematologic Malignancies
Neoplastic cells rewire their metabolism, acquiring a selective advantage over normal cells and a protection from therapeutic agents. The mammalian Target of Rapamycin (mTOR) is a serine/threonine kinase involved in a variety of cellular activities, including the control of metabolic processes. mTOR...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-02-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/9/2/404 |
| _version_ | 1827880871614480384 |
|---|---|
| author | Simone Mirabilii Maria Rosaria Ricciardi Agostino Tafuri |
| author_facet | Simone Mirabilii Maria Rosaria Ricciardi Agostino Tafuri |
| author_sort | Simone Mirabilii |
| collection | DOAJ |
| description | Neoplastic cells rewire their metabolism, acquiring a selective advantage over normal cells and a protection from therapeutic agents. The mammalian Target of Rapamycin (mTOR) is a serine/threonine kinase involved in a variety of cellular activities, including the control of metabolic processes. mTOR is hyperactivated in a large number of tumor types, and among them, in many hematologic malignancies. In this article, we summarized the evidence from the literature that describes a central role for mTOR in the acquisition of new metabolic phenotypes for different hematologic malignancies, in concert with other metabolic modulators (AMPK, HIF1α) and microenvironmental stimuli, and shows how these features can be targeted for therapeutic purposes. |
| first_indexed | 2024-03-12T18:29:12Z |
| format | Article |
| id | doaj.art-af235ffe00a04c5c915061b5f4519783 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-12T18:29:12Z |
| publishDate | 2020-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-af235ffe00a04c5c915061b5f45197832023-08-02T08:21:19ZengMDPI AGCells2073-44092020-02-019240410.3390/cells9020404cells9020404mTOR Regulation of Metabolism in Hematologic MalignanciesSimone Mirabilii0Maria Rosaria Ricciardi1Agostino Tafuri2Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Rome, ItalyDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Rome, ItalyDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Rome, ItalyNeoplastic cells rewire their metabolism, acquiring a selective advantage over normal cells and a protection from therapeutic agents. The mammalian Target of Rapamycin (mTOR) is a serine/threonine kinase involved in a variety of cellular activities, including the control of metabolic processes. mTOR is hyperactivated in a large number of tumor types, and among them, in many hematologic malignancies. In this article, we summarized the evidence from the literature that describes a central role for mTOR in the acquisition of new metabolic phenotypes for different hematologic malignancies, in concert with other metabolic modulators (AMPK, HIF1α) and microenvironmental stimuli, and shows how these features can be targeted for therapeutic purposes.https://www.mdpi.com/2073-4409/9/2/404mtorhematologic malignanciescell metabolism |
| spellingShingle | Simone Mirabilii Maria Rosaria Ricciardi Agostino Tafuri mTOR Regulation of Metabolism in Hematologic Malignancies Cells mtor hematologic malignancies cell metabolism |
| title | mTOR Regulation of Metabolism in Hematologic Malignancies |
| title_full | mTOR Regulation of Metabolism in Hematologic Malignancies |
| title_fullStr | mTOR Regulation of Metabolism in Hematologic Malignancies |
| title_full_unstemmed | mTOR Regulation of Metabolism in Hematologic Malignancies |
| title_short | mTOR Regulation of Metabolism in Hematologic Malignancies |
| title_sort | mtor regulation of metabolism in hematologic malignancies |
| topic | mtor hematologic malignancies cell metabolism |
| url | https://www.mdpi.com/2073-4409/9/2/404 |
| work_keys_str_mv | AT simonemirabilii mtorregulationofmetabolisminhematologicmalignancies AT mariarosariaricciardi mtorregulationofmetabolisminhematologicmalignancies AT agostinotafuri mtorregulationofmetabolisminhematologicmalignancies |